Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis

Main Inclusion Criteria: * Patients must have the below proven, probable or possible deep mycosis; 1. invasive aspergillosis 2. chronic pulmonary aspergillosis 3. mucormycosis 4. cryptococcosis * Female patients must be non-lactating and at no risk for pregnancy. Main Exclusion Criteria: * Women who are pregnant or breastfeeding. * Patients with hypersensitivity to any of the components of the azole class of antifungals or the investigational product. * Patients at high risk for QT/QTc prolongation, or patients with risk factors for torsades de pointes, or taking concomitant medications known to prolong the QT/QTc interval. * Patients with a history of short QT syndrome. * Patients with liver dysfunction at enrollment. * Patients with moderate to severe kidney dysfunction at enrollment. * Patients who receive prohibited concomitant drugs. * Patients with any other fungal infection other than Aspergillus species, order Mucorales, or Cryptococcus species. * Patients who are not expected to survive study duration. * Patients with an underlying disease, complication or general condition that would complicate safety and efficacy evaluations. * Patients with a history of taking voriconazole for deep mycosis and showing no response to this treatment. * Patients taking systemic antifungals who are unable to stop taking these drugs during the study, or who are showing signs of improvement in their symptoms of deep mycosis as a result of these drugs.